ReviewInternational journal of ophthalmology2022
Inflammation and dry eye disease-where are we?
Review in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 64 citations in OpenAlex.
- Clinical Efficacy and Safety of Preservative Free Cyclosporine in Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Trial
- Application of large language models in clinical decision-making for dry eye disease.BMC medical informatics and decision making · 2026Article
- Natural Products Targeting Immune Mechanisms in Ocular Inflammation: Uveitis and Dry Eye.Current issues in molecular biology · 2026Review
- A comprehensive review of tear fluid proteome alterations in dry eye disease: Insights into pathophysiology and biomarker potential.The ocular surface · 2026Review
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects.Animal models and experimental medicine · 2026Review
- Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone.Investigative ophthalmology & visual science · 2026Article
- Effects of a Novel Dexamethasone Hydrogel Drug Delivery System on Cytokine and Mucin Expression in a Three-Dimensional In Vitro Conjunctival Inflammation Model.Investigative ophthalmology & visual science · 2026Article
- Real-World Treatment Patterns and Clinical Outcomes with Cyclosporine 0.1% in Semifluorinated Alkane for Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Improving the post-oculoplastic tear film: trehalose as a critical adjunct.International journal of ophthalmology · 2026Article
- Immuno-inflammatory axis of menopausal dry eye: from hormonal fluctuations to ocular surface dysregulation.Frontiers in immunology · 2026Review
- Imaging Approaches for the Diagnosis of Dry Eye: A Review.Diagnostics (Basel, Switzerland) · 2026Review
- Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control.Frontiers in ophthalmology · 2026Article
- Platelets in Dry Eye Disease: A Narrative Review of Biological Mechanisms and Therapeutic Applications Derived from Platelets.Life (Basel, Switzerland) · 2025Review
- Polyphenol-Loaded Nanodevices as Innovative Therapeutic Strategies for Dry Eye Disease: Advances and Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
- Translating Biomarker Discovery: From Bench to Bedside in Dry Eye Disease.International journal of molecular sciences · 2025Review
- Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey in the USA and Canada.Ophthalmology and therapy · 2025Article
- Oral Intake ofBiomedicines · 2025Article
- Role of Chinese Medicine Monomers in Dry Eye Disease: Breaking the Vicious Cycle of Inflammation.Pharmacology research & perspectives · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of inflammation in dry eye disease (DED) results in increased patient symptomatology, ocular surface damage and worsening tear dysfunction. It also affects the health of meibomian glands and their secretions which further aggravates ocular surface disease. This article reviews current knowledge regarding ocular surface inflammation in DED and explores the relationships between the vicious cycles of DED, inflammation and meibomian gland dysfunction (MGD). The clinical evaluation of eyes with such changes, markers that identify the presence of inflammation on the ocular surface and current treatment options are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.